Royal DSM N.V. (RDSMY.PK), a life and material science company, reported a 2% increase in first-quarter EBITDA to 311 million euros, from 306 million euros in the prior-year quarter, despite a negative caprolactam effect of 65 million euros.
According to the company, Life Sciences delivered growth once again, driven by Nutrition, and Materials Sciences performed well, except for caprolactam. During the recent quarter, DSM benefited from the sale of certain DSM Resins & Functional Materials related distribution activities.
However, net profit before exceptional items was 121 million euros, down 17% compared with last year figure of 145 million euros, due to higher depreciation and amortization mainly due to the acquisitions of last year as well as higher net finance costs. Also, quarterly core net profit slid to 129 million euros, or 0.76 euros per share, from 149 million euros, or 0.91 euros per share. Including exceptional items, net profit amounted to 119 million euros, or 0.69 euros per share in the quarter.
Net sales for the period grew year-over-year to 2.38 billion euros, from 2.29 billion euros.
For comments and feedback: editorial@rttnews.com